---
title: "Qulipta (atogepant) in preventive treatment of migraine: Safety questions"
description: "Safety questions on Qulipta (atogepant) in preventive treatment of migraine, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects, Safety evidence, and Warnings. Questions: What are the most common side effects of Qulipta? How many patients were studied for Qulipta safety? Does Qulipta cause weight loss? Can Qulipta cause liver problems? 6 further questions follow. 10 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Qulipta (atogepant) in preventive treatment of migraine: Safety questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Qulipta](https://www.rxabbvie.com/pdf/qulipta_pi.pdf)

## Side effects

<a id="qulipta-side-effects"></a>

### What are the most common side effects of Qulipta?

> “The most common adverse reactions (incidence at least 4% and greater than placebo) are nausea, 
> constipation, and fatigue/somnolence.”

Source: [QULIPTA: Prescribing information, page 4, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=4)

> “Table 2: Adverse Reactions Occurring with an Incidence of At Least 2% for QULIPTA 
> and Greater than Placebo in Studies 1, 2, and 3<sup>*</sup> 
>
> Placebo 
>
> (N= 663) 
> % 
> QULIPTA  
> 10 mg 
> (N=314) 
> % 
> QULIPTA  
> 30 mg 
> (N=411) 
> % 
> QULIPTA  
> 60 mg 
> (N=678) 
> % 
> Nausea 
> 3 
> 5 
> 6 
> 9 
> Constipation 
> 2 
> 6 
> 6 
> 8 
> Fatigue/Somnolence 
> 4 
> 4 
> 4 
> 5 
> Decreased Appetite 
> <1 
> 2 
> 1 
> 3 
> Dizziness 
> 2 
> 2 
> 2 
> 3 
> * 10 mg and 30 mg incidence from Studies 1 and 2; 60 mg pooled incidence from Studies 1, 2, and 3.”

Source: [QULIPTA: Prescribing information, page 4, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=4)

> “The adverse reactions that most commonly led to discontinuation of QULIPTA in these studies 
> were nausea (0.6%), constipation (0.5%), and fatigue/somnolence (0.2%).”

Source: [QULIPTA: Prescribing information, page 4, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=4)

Note: Table 2 columns are placebo, QULIPTA 10 mg, QULIPTA 30 mg, and QULIPTA 60 mg, in that order; each row lists its percentages in that order.

<a id="qulipta-weight-loss"></a>

### Does Qulipta cause weight loss?

> “Decreases in Body Weight 
> In Study 1, Study 2, and Study 3, the proportion of patients with a weight decrease of at least 7% 
> at any point was 2.5% for placebo, 3.8% for QULIPTA 10 mg, 3.2% for QULIPTA 30 mg, and 
> 5.3% for QULIPTA 60 mg.”

Source: [QULIPTA: Prescribing information, page 5, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=5)

> “Decreased Appetite 
> <1 
> 2 
> 1 
> 3”

Source: [QULIPTA: Prescribing information, page 4, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=4)

Note: The second passage is the decreased appetite row of Table 2 (Studies 1, 2, and 3): placebo, QULIPTA 10 mg, 30 mg, and 60 mg, in that order.

<a id="qulipta-liver"></a>

### Can Qulipta cause liver problems?

> “Liver Enzyme Elevations 
> In Study 1, Study 2, and Study 3, the rate of transaminase elevations over 3 times the upper limit 
> of normal was similar between patients treated with QULIPTA (0.9%) and those treated with”

Source: [QULIPTA: Prescribing information, page 4, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=4)

> “placebo (1.2%). However, there were cases with transaminase elevations over 3 times the upper 
> limit of normal that were temporally associated with QULIPTA treatment; these were 
> asymptomatic and resolved within 8 weeks of discontinuation. There were no cases of severe 
> liver injury or jaundice.”

Source: [QULIPTA: Prescribing information, page 5, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=5)

> “Due to a potential for liver injury in patients with severe 
> hepatic impairment, avoid use of QULIPTA in patients with severe hepatic impairment”

Source: [QULIPTA: Prescribing information, page 10, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=10)

Note: The first two passages are from Adverse Reactions (section 6.1) and are one sentence that continues from page 4 to page 5 of the Prescribing Information; the third is from Clinical Pharmacology (section 12.3).

## Safety evidence

<a id="qulipta-safety-exposure"></a>

### How many patients were studied for Qulipta safety?

> “The safety of QULIPTA was evaluated in 2657 patients with migraine who received at least one 
> dose of QULIPTA. Of these, 1225 patients were exposed to QULIPTA for at least 6 months, and 
> 826 patients were exposed for 12 months.”

Source: [QULIPTA: Prescribing information, page 4, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=4)

## Warnings

<a id="qulipta-hypersensitivity"></a>

### Can Qulipta cause allergic reactions?

> “Hypersensitivity reactions, including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial 
> edema, have been reported with use of QULIPTA [see Adverse Reactions (6.2)]. 
> Hypersensitivity reactions can occur days after administration. If a hypersensitivity reaction 
> occurs, discontinue QULIPTA and institute appropriate therapy [see Contraindications (4)].”

Source: [QULIPTA: Prescribing information, page 3, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=3)

<a id="qulipta-hypertension"></a>

### Can Qulipta raise blood pressure (hypertension)?

> “Development of hypertension and worsening of pre-existing hypertension have been reported 
> following the use of CGRP antagonists, including QULIPTA, in the postmarketing setting. Some 
> of the patients who developed new-onset hypertension had risk factors for hypertension. There 
> were cases requiring initiation of pharmacological treatment for hypertension and, in some cases, 
> hospitalization. Hypertension may occur at any time during treatment, but was most frequently 
> reported within 7 days of therapy initiation. QULIPTA was discontinued in many of the reported 
> cases. 
> Monitor patients treated with QULIPTA for new-onset hypertension, or worsening of 
> pre-existing hypertension, and consider whether discontinuation of QULIPTA is warranted if 
> evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.”

Source: [QULIPTA: Prescribing information, page 3, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=3)

<a id="qulipta-raynauds"></a>

### Can Qulipta cause Raynaud’s phenomenon?

> “Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s 
> phenomenon have been reported in the postmarketing setting following the use of CGRP 
> antagonists, including QULIPTA. In reported cases with small molecule CGRP antagonists, 
> symptom onset occurred a median of 1.5 days following dosing. Many of the cases reported 
> serious outcomes, including hospitalizations and disability, generally related to debilitating pain. 
> In most reported cases, discontinuation of the CGRP antagonist resulted in resolution of 
> symptoms. 
> QULIPTA should be discontinued if signs or symptoms of Raynaud’s phenomenon develop, and 
> patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a 
> history of Raynaud’s phenomenon should be monitored for, and informed about the possibility 
> of, worsening or recurrence of signs and symptoms.”

Source: [QULIPTA: Prescribing information, page 3, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=3)

<a id="qulipta-contraindications"></a>

### Who should not take Qulipta (contraindications)?

> “QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of 
> the components of QULIPTA. Reactions have included anaphylaxis and dyspnea [see Warnings 
> and Precautions (5.1)].”

Source: [QULIPTA: Prescribing information, page 3, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=3)

> “Patients with severe hepatic impairment should avoid use of QULIPTA. For chronic migraine, use of QULIPTA is not recommended for patients who take strong or moderate CYP3A4 inducers, or those with severe renal impairment, or end-stage renal disease.<sup>1</sup>”

Source: [QULIPTA: Frequently Asked Questions for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/frequently-asked-questions#:~:text=Patients%20with%20severe%20hepatic%20impairment,renal%20impairment%2C%20or%20end%2Dstage%20renal)

On the page, select: Who shouldn’t take QULIPTA?

Note: The first passage is section 4 (Contraindications) of the Prescribing Information. The second, from the FAQ on the Qulipta HCP site, lists patients in whom the label recommends avoiding QULIPTA or does not recommend it.

## Safety

<a id="qulipta-qt-prolongation"></a>

### Does Qulipta prolong the QT interval?

> “At a dose 5 times the maximum recommended daily dose, QULIPTA does not prolong the QT 
> interval to any clinically relevant extent.”

Source: [QULIPTA: Prescribing information, page 9, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=9)

<a id="qulipta-carcinogenicity-animal"></a>

### Did Qulipta cause tumors in animal studies?

> “Atogepant was administered orally to mice (0, 5, 20, or 75 mg/kg/day in males; 0, 5, 30, 
> 160 mg/kg/day in females) and rats (0, 10, 20, or 100 mg/kg in males; 0, 25, 65, or 200 mg/kg in”

Source: [QULIPTA: Prescribing information, page 11, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=11)

> “females) for up to 2 years. There was no evidence of drug-related tumors in either species.”

Source: [QULIPTA: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=12)

> “Atogepant was negative in in vitro (Ames, chromosomal aberration test in Chinese Hamster 
> Ovary cells) and in vivo (rat bone marrow micronucleus) assays.”

Source: [QULIPTA: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=12)

Note: These are nonclinical (animal and laboratory) results from section 13 of the Prescribing Information; the first two passages are one sentence that continues from page 11 to page 12.

## Related pages
- [Medical information: Qulipta (atogepant): Preventive treatment of migraine](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine)
- [Indication](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/access-and-coverage)
